What is on the Horizon for Adjuvant Therapy in Early-Stage Breast Cancer?
Expert medical oncologists take a step into the future and discuss developments within the adjuvant setting of early-stage breast cancer they are most excited about.
Managing Toxicities and Adverse Events of CDK 4/6 Inhibitors
Stephanie Graff, MD, and Rachel Layman, MD, review common toxicities and adverse effects to watch out for with endocrine therapy and CDK4/6 inhibitors, and how to manage these.
Impact of Trial Data on Clinical Practice
Expert medical oncologists talk about the impact of NATALEE trial data on their medical practice.
Key Findings from the NATALEE Trial
Stephanie Graff, MD, and Rachel Layman, MD, discuss the design and results of the NATALEE trial, which evaluated adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer.
Risk of Recurrence
Stephanie Graff, MD, describes her impression of the case and discusses the risk for recurrence in this particular patient.
Clinical Case 2: High-Risk Early-Stage HR+ Breast Cancer
Rachel Layman, MD, presents a clinical case of a patient who is diagnosed with HR+ early-stage breast cancer.
Selecting Endocrine Therapy in BRCA1/BRCA2+ Breast Cancer
Experts in breast oncology discuss how they select endocrine therapy in BRCA1/BRCA2+ breast cancer.
Implementing Trial Data to Our Practice
Stephanie Graff, MD, and Rachel Layman, MD, discuss how they would apply the results of the monarchE trial to clinical case scenarios.
Dosing CDK 4/6 Inhibitors
Rachel Layman, MD, summarizes how to dose CDK4/6 inhibitors in different clinical settings.
Age-Dependent Results With CDK 4/6 Inhibitors
Experts in breast oncology review age-dependent outcomes with CDK 4/6 inhibitors.
Individualizing Care with CDK 4/6 Inhibitors
Stephanie Graff, MD, and Rachel Layman, MD, discuss how to individualize care with CDK4/6 inhibitors in patients with high-risk early breast cancer.
Key Findings from the monarchE Trial
Stephanie Graff, MD, and Rachel Layman, MD, discuss the design and results of the monarchE trial, which evaluated abemaciclib plus endocrine therapy for HR+, HER2 negative, node positive, high-risk early breast cancer.
Endocrine Therapy for Early-Stage Breast Cancer
Expert medical oncologists provide an overview of current endocrine therapy approved for early-stage breast cancer.
Risk Factors and the Treatment Plan
Rachel Layman, MD, describes her impression of the case and discusses risk assessment and a treatment plan for the patient.
Clinical Case 1: High-Risk Early-Stage HR+ Breast Cancer
Stephanie Graff, MD, presents a clinical case of a patient who is diagnosed with HR+ early-stage breast cancer.
Dr Wong on Hypofractionation vs Conventional Fractionation in Breast Cancer Postmastectomy
Immunotherapy Combinations Deliver Outcome-Shifting Responses in Lymphoma
Dr Deek on the Investigation of Immune Cell Infiltration in MIBC
Hypofractionated and Conventionally Fractionated Radiotherapy Generate Similar QOL, Safety in Breast Cancer
2 Clarke Drive Cranbury, NJ 08512